Phase III MEASURE 1 study for Cosentyx shows improvements in ankylosing spondylitis to 5 years.- Novartis.

Novartis announced five-year data from the ongoing extensions of the phase III MEASURE 1 study for Cosentyx (secukinumab) in patients with ankylosing spondylitis (AS). New long-term data from MEASURE 1 confirm that Cosentyx provides sustained improvements in the signs and symptoms of AS out to five years. A total of 290 of 371 patients completed the trial, after which 274 patients entered a three-year extension period. Over 80% of patients who participated in the extension phase of the study completed five years of Cosentyx treatment. 56% of patients on Cosentyx 75mg were escalated to Cosentyx 150 mg after Week 168. Improvements in ASAS 20 and ASAS 40 responses were sustained out to five years in all dosage cohorts.

In the dose escalation cohort, ASAS 20 responses improved from 74% for Cosentyx 75mg to 82% for Cosentyx 150 mg after 72 weeks. The safety profile of Cosentyx was shown to be consistent with that previously seen in clinical trials across multiple indications. These new data will be presented at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting.